Business Context and Reporting Period
Company: Autolus Therapeutics Plc
Filing Type: Form 8-K (Current Report)
Date of Report: March 21, 2024
Subject: Non-reliance on previously issued financial statements due to an accounting error regarding the classification of U.K. research and development (R&D) tax credits.
Key Financial Metrics
This filing does not report current period revenue, profit, cash flow, or liquidity metrics. It addresses a specific accounting restatement affecting prior periods:
- Income Tax Benefit Adjustment: Reduced by $24.6 million for the year ended December 31, 2022, and $24.0 million for the year ended December 31, 2021.
- R&D Expense Adjustment: Corresponding reductions in research and development expenses and total operating expenses for the same periods.
- Net Loss Impact: No impact on net loss attributable to ordinary shareholders for any affected period.
- Balance Sheet/Cash Flow: No impact on the consolidated balance sheet, statement of cash flows, or statement of stockholders' equity.
Material Changes Versus Prior Period
The filing identifies a material accounting error in the classification of U.K. SME tax credits. Historically, the Company recorded these credits as a reduction of income tax expense. The Company determined they should have been recorded as a reduction of R&D expenses. Consequently, the audited consolidated financial statements for the years ended December 31, 2022 and 2021, and the quarterly statements of operations within those years, are no longer reliable.
Guidance, Outlook, and Management Commentary
Management Action: The Audit Committee, upon management's recommendation and discussion with Ernst & Young LLP, concluded that the prior financial statements should no longer be relied upon.
Remediation Plan: The Company intends to correct the error in its upcoming Annual Report on Form 10-K for the year ended December 31, 2023. This filing will present restated audited consolidated statements of operations and comprehensive loss for 2022 and 2021, along with unaudited footnote disclosures for affected quarters in 2023 and 2022.
Amendment Status: The Company has not amended and does not intend to amend prior Annual Reports on Form 20-F, Quarterly Reports on Form 10-Q, or Reports on Form 6-K.
Investor Verification Checklist
- Verify the upcoming Form 10-K for the year ended December 31, 2023, to review the restated financial statements for 2021 and 2022.
- Confirm the specific impact of the reclassification on R&D expense ratios and operating margins for the restated periods.
- Review the unaudited footnote disclosures in the 2023 10-K regarding the corrected amounts for quarters within 2022 and 2023.
- Ensure no other financial statement line items were affected by this classification error.